The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Open accessAbstract
IMPORTANCE: Off-label use of prescription drugs has been identified as an important contributor to preventable adverse drug events (ADEs) in children. Despite concerns regarding adverse outcomes, to date, no systematic investigation of the effects of off-label drug use in adult populations has been performed. OBJECTIVE: To monitor and evaluate off-label use of prescription drugs and its effect on ADEs in an adult population. DESIGN, SETTING, AND PARTICIPANTS: A cohort of 46,021 patients who received 151,305 incident prescribed drugs was assembled from primary care clinics in Quebec, Canada, using the Medical Office of the XXIst Century electronic health record, which supports documentation of treatment indications and treatment outcomes. Prescriptions dispensed from January 1, 2005, through December 30, 2009, were followed up from the date of the prescription to the date the drug use was discontinued, the end of treatment, or the end of follow-up (December 30, 2010). Data were analyzed from January 5, 2012, to March 15, 2015. EXPOSURES: Off-label prescription drug use with and without strong scientific evidence. MAIN OUTCOMES AND MEASURES: Adverse drug events in off-label use with and without strong scientific evidence. Analysis used multivariate marginal Cox proportional hazards regression for clustered data with the drug as the unit of analysis. RESULTS: A total of 3484 ADEs were found in the 46,021 study patients, with an incidence rate of 13.2 per 10,000 person-months. The rate of ADEs for off-label use (19.7 per 10,000 person-months) was higher than that for on-label use (12.5 per 10,000 person-months) (adjusted hazard ratio [AHR], 1.44; 95% CI, 1.30-1.60). Off-label use lacking strong scientific evidence had a higher ADE rate (21.7 per 10,000 person-months) compared with on-label use (AHR, 1.54; 95% CI, 1.37-1.72). However, off-label use with strong scientific evidence had the same risk for ADEs as on-label use (AHR, 1.10; 95% CI, 0.88-1.38). The risks for ADEs were higher for drugs approved from 1981 to 1995 (14.4 per 10,000 person-months; AHR, 1.62; 95% CI, 1.45-1.80) and for those used by women (14.3 per 10,000 person-months; AHR, 1.17; 95% CI, 1.06-1.28), patients receiving 5 to 7 drugs (12.1 per 10,000 person-months; AHR, 3.23; 95% CI, 2.66-3.92), and patients receiving cardiovascular drugs (15.9 per 10,000 person-months; AHR, 3.30; 95% CI, 2.67-4.08) and anti-infectives (66.2 per 10,000 person-months; AHR, 6.33; 95% CI, 4.58-8.76). Patients with a 1-unit increase in the continuity of care index had a 19% increase in ADEs (AHR, 1.19; 95% CI, 1.12-1.26). CONCLUSIONS AND RELEVANCE: Off-label use of prescription drugs is associated with ADEs. Caution should be exercised in prescribing drugs for off-label uses that lack strong scientific evidence. Future electronic health records should be designed to enable postmarket surveillance of treatment indications and treatment outcomes to monitor the safety of on- and off-label uses of drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Adverse Drug Events in Ambulatory Care
Gandhi, T. K., Weingart, S. N., Borus, J., Seger, A. C., Peterson, J., Burdick, E., Seger, D. L., Shu, K., Federico, F., Leape, L. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa020703 · Cited by 1,345
National Surveillance of Emergency Department Visits for Outpatient Adverse Drug Events
Budnitz, D. S., Pollock, D. A., Weidenbach, K. N., Mendelsohn, A. B., Schroeder, T. J., & Annest, J. L. (2006) · JAMA · doi:10.1001/jama.296.15.1858 · Cited by 893
Off-label prescribing among office-based physicians
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1021 · Cited by 711 · cited 2×
“Strong evidence exists when (1) the drug is effective or favors efficacy for the off-label treatment indication, (2) the drug is recommended for at least most patients with the off-label treatment indication, and (3) the Research Original Investigation Off-label Drug Use and Adverse Drug Events in Adults”
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006221 · Cited by 677
Polypharmacy and Prescribing Quality in Older People
Steinman, M. A., Seth Landefeld, C., Rosenthal, G. E., Berthenthal, D., Sen, S., & Kaboli, P. J. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00889.x · Cited by 537
Tamblyn, R., Abrahamowicz, M., Dauphinee, D., Wenghofer, E., Jacques, A., Klass, D., Smee, S., Blackmore, D., Winslade, N., Girard, N., et al. (2007) · JAMA · doi:10.1001/jama.298.9.993 · Cited by 448
Self-citationAdmissions to hospital caused by adverse drug reactions: cross sectional incidence study
Pouyanne, P. (2000) · BMJ · doi:10.1136/bmj.320.7241.1036 · Cited by 444
Advances in Inflammation Research.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-6-885_1 · Cited by 387
Cited by
Wong, J., Motulsky, A., Abrahamowicz, M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2017) · BMJ · doi:10.1136/bmj.j603 · Cited by 221
Self-citationOff-Label Medication: From a Simple Concept to Complex Practical Aspects
Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910447 · Cited by 58
Bronskill, S. E., Campitelli, M. A., Iaboni, A., Herrmann, N., Guan, J., Maclagan, L. C., Watt, J., Rochon, P. A., Morris, A. M., Jeffs, L., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15519 · Cited by 54
Off-Label Use vs Off-Label Marketing of Drugs
Van Norman, G. A. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.12.011 · Cited by 49
Gjerden, P., Bramness, J. G., Tvete, I. F., & Slørdal, L. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2281-8 · Cited by 48
Metadata
- Authors
- Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-01-01
- Volume
- 176
- Issue
- 1
- Pages
- 55
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2157789635
- Cited by
- 262
- References
- 42
- FWCI
- 41.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. https://app.cochat.ai/papers/10.1001/jamainternmed.2015.6058
- The paper
- Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. (2016). Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2015.6058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.